Posted in | News | Nanomedicine | Nanobusiness

Nano-Diagnostics Company Appoints Gannon to Scientific Advisory Board

AION Diagnostics Inc, a nano-diagnostics company commercializing medical imaging agents, announced today the appointment of William E. Gannon Jr., M.D., M.B.A., expert in clinical and regulatory affairs, to its Scientific Advisory Board.

Dr Gannon is founder and Chief Medical Officer of Apthera Inc., a company commercializing a peptide-based immunotherapy for the treatment of early-stage Her2-positive breast cancer. Dr. Gannon is an expert in the development, commercialization, marketing and management of health-care products and medical devices. With extensive senior management level experience at two of the worlds largest Regulatory Contract Research Organizations; Quintiles and Pharmaceutical Product Development Inc, Dr. Gannon also holds expertise in the management of regulatory global submissions. This includes experience with FDA processes, European (ISO 9000), Canadian and Japanese regulatory environments as well as IBC AHA and JCAHO affairs. Dr. Gannon is an experienced biopharmaceutical executive, most recently with oncology focused company, Celsion Corporation.

'Dr. Gannon's regulatory and clinical expertise will further support and accelerate commercialization of AION's products,' reported Dr. Anna Kluczewska, President and CEO of AION.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.